{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T08:09:39Z","timestamp":1771574979995,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T00:00:00Z","timestamp":1697932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.rpth.2023.102240","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:09:09Z","timestamp":1698786549000},"page":"102240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Use of direct oral anticoagulants for venous thromboembolism treatment at extremes of body weight, renal and liver function: an illustrated review"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5064-9375","authenticated-orcid":false,"given":"Victoria","family":"Speed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4315-3704","authenticated-orcid":false,"given":"Julia","family":"Czuprynska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-8294","authenticated-orcid":false,"given":"Jignesh P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5630-7990","authenticated-orcid":false,"given":"Roopen","family":"Arya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2023.102240_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.15386\/mpr-1372","article-title":"Association between obesity and venous thromboembolism","volume":"93","author":"Hotoleanu","year":"2020","journal-title":"Med Pharm Rep"},{"key":"10.1016\/j.rpth.2023.102240_bib3","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.amjmed.2005.03.012","article-title":"Obesity as a risk factor in venous thromboembolism","volume":"118","author":"Stein","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2023.102240_bib4","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/archinte.168.15.1678","article-title":"Overweight, obesity, and the risk of recurrent venous thromboembolism","volume":"168","author":"Eichinger","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rpth.2023.102240_bib5","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102240_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11318100-000000000-00000","article-title":"Effect of obesity on the pharmacokinetics of drugs in humans","volume":"49","author":"Hanley","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2023.102240_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","article-title":"Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters","volume":"14","author":"Smit","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.rpth.2023.102240_bib8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.clpt.6100381","article-title":"Dosing in obesity: a simple solution to a big problem","volume":"82","author":"Han","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.rpth.2023.102240_bib9","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1517\/17425255.2011.570331","article-title":"The effects of obesity on drug pharmacokinetics in humans","volume":"7","author":"Morrish","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.rpth.2023.102240_bib10","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102240_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102240_bib12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"key":"10.1016\/j.rpth.2023.102240_bib13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH16-02-0087","article-title":"Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT\/PE studies","volume":"116","author":"Di Nisio","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102240_bib14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102240_bib15","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1007\/s12325-021-01716-8","article-title":"Efficacy, safety, and exposure of apixaban in patients with high body weight or obesity and venous thromboembolism: insights from AMPLIFY","volume":"38","author":"Cohen","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.rpth.2023.102240_bib16","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102240_bib17","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of\u00a0acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.102240_bib18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/ejh.13471","article-title":"Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight","volume":"105","author":"Wysokinski","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2023.102240_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2018.03.060","article-title":"Impact of BMI on clinical outcomes of NOAC therapy in daily care\u2014results of the prospective Dresden NOAC Registry (NCT01588119)","volume":"262","author":"Tittl","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.rpth.2023.102240_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11239-020-02199-0","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data","volume":"51","author":"Costa","year":"2021","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2023.102240_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.thromres.2019.08.021","article-title":"Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: comparative effectiveness, safety, and costs","volume":"182","author":"Spyropoulos","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2023.102240_bib22","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(19)30086-9","article-title":"Efficacy\u00a0and safety of direct oral factor Xa inhibitors compared with\u00a0warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data","volume":"6","author":"Kushnir","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2023.102240_bib23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1060028019886092","article-title":"Rivaroxaban versus warfarin for stroke prevention and venous thromboembolism treatment in extreme obesity and high body weight","volume":"54","author":"Perales","year":"2020","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rpth.2023.102240_bib24","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.thromres.2020.01.011","article-title":"Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism","volume":"187","author":"Quan","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2023.102240_bib25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects","volume":"47","author":"Kubitza","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.rpth.2023.102240_bib26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/rth2.12146","article-title":"Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study","volume":"2","author":"Piran","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102240_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-0040-1715834","article-title":"Direct oral anticoagulant concentrations in obese and high body weight patients: a cohort study","volume":"121","author":"Martin","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102240_bib28","first-page":"200","article-title":"Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity","volume":"10","author":"Cohen","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.rpth.2023.102240_bib29","first-page":"1105","article-title":"Apixaban is safe and effective in morbidly obese patients: a retrospective analysis of 390 patients with BMI\u2265 40","volume":"130","author":"Choi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.102240_bib30","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bcp.12114","article-title":"Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects","volume":"76","author":"Upreti","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2023.102240_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2019.08.014","article-title":"Validation of apixaban anti-factor Xa assay and impact of body weight","volume":"182","author":"Wasan","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2023.102240_bib32","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/j.clinthera.2021.07.003","article-title":"Pharmacokinetics of direct oral anticoagulants in patients with atrial fibrillation and extreme obesity","volume":"43","author":"Russo","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.rpth.2023.102240_bib33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2023.102240_bib34","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2023.102240_bib35","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1111\/jth.15520","article-title":"Influence of body mass index on clinical outcomes in venous thromboembolism: insights from GARFIELD-VTE","volume":"19","author":"Weitz","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102240_bib36","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1538-7836.2008.02907.x","article-title":"Body mass index and mortality in patients with acute venous thromboembolism: findings from the RIETE registry","volume":"6","author":"Barba","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102240_bib37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2023.102240_bib38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/rth2.12036","article-title":"Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism","volume":"1","author":"Moustafa","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.102240_bib39","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40262-023-01222-w","article-title":"Insights into the pharmacokinetics and pharmacodynamics of\u00a0direct oral anticoagulants in older adults with atrial fibrillation: a\u00a0structured narrative review","volume":"62","author":"Edwina","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2023.102240_bib40","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/jgs.16992","article-title":"Muscle mass and direct oral anticoagulant activity in older adults with atrial fibrillation","volume":"69","author":"Bendayan","year":"2021","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.rpth.2023.102240_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.thromres.2020.11.022","article-title":"Influence of low body weight on long-term clinical outcomes in patients with venous thromboembolism: from the COMMAND VTE registry","volume":"198","author":"Kaneda","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2023.102240_bib42","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2023.102240_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2023.102240_bib44","first-page":"2015","article-title":"A\u00a0systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease","volume":"35","author":"Parker","year":"2022","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.rpth.2023.102240_bib45","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0272-6386(95)90123-X","article-title":"Defective platelet aggregation in uremia is transiently worsened by hemodialysis","volume":"25","author":"Sreedhara","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rpth.2023.102240_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22886","article-title":"Assessment of outcomes among patients with venous thromboembolism with and without chronic kidney disease","volume":"3","author":"Goto","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2023.102240_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-048619","article-title":"Comparative efficacy and safety of oral anticoagulants for the treatment of venous thromboembolism in the patients with different renal functions: a systematic review, pairwise and network meta-analysis","volume":"12","author":"Su","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.rpth.2023.102240_bib48","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11239-022-02758-7","article-title":"Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance\u00a0< 30 mL\/min","volume":"55","author":"Cline","year":"2023","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2023.102240_bib50","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF","volume":"67","author":"Chan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2023.102240_bib51","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11239-022-02650-4","article-title":"Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy","volume":"54","author":"Chen","year":"2022","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.rpth.2023.102240_bib52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2023.102240_bib53","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1161\/CIRCULATIONAHA.116.024666","volume":"135","author":"Lindner","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2023.102240_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0278693","article-title":"Impact of increased kidney function on clinical and biological outcomes in real-world patients treated with direct oral anticoagulants","volume":"17","author":"Corrochano","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2023.102240_bib57","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment","volume":"48","author":"Stangier","year":"2008","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.rpth.2023.102240_bib58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2023.102240_bib59","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jcph.550","article-title":"An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics","volume":"55","author":"Mendell","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.rpth.2023.102240_bib60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40268-021-00359-y","article-title":"Apixaban pharmacokinetics and pharmacodynamics in subjects with mild or moderate hepatic impairment","volume":"21","author":"Frost","year":"2021","journal-title":"Drugs R D"},{"key":"10.1016\/j.rpth.2023.102240_bib61","doi-asserted-by":"crossref","first-page":"e13397","DOI":"10.1111\/eci.13397","article-title":"Direct oral anticoagulants and advanced liver disease: a systematic review and meta-analysis","volume":"51","author":"Menichelli","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.rpth.2023.102240_bib62","first-page":"315","article-title":"Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges","volume":"31","author":"Mantaka","year":"2018","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.rpth.2023.102240_bib63","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dld.2021.07.039","article-title":"Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis","volume":"54","author":"Koh","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.rpth.2023.102240_bib64","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1007\/s12072-021-10247-x","article-title":"A\u00a0network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis","volume":"15","author":"Ng","year":"2021","journal-title":"Hep Int"},{"key":"10.1016\/j.rpth.2023.102240_bib65","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/17474086.2023.2184340","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: recent updates for patients with liver cirrhosis","volume":"16","author":"Caiano","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2023.102240_bib66","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923005009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923005009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:28:21Z","timestamp":1762864101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037923005009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S2475037923005009"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2023.102240","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of direct oral anticoagulants for venous thromboembolism treatment at extremes of body weight, renal and liver function: an illustrated review","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2023.102240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102240"}}